MarketCap
Facebook
X
TelegramAnnual report 2024
added 01-24-2026
Galapagos NV EBITDA per Share 2011-2026 | GLPG
Annual EBITDA per Share Galapagos NV
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | -2.53 | -2.75 | 6.4 K | -0.9 | -1.81 | 0.0608 | -2.41 | -1.04 | -0.284 | -0.0282 | - |
All numbers in EUR currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 6.4 K | -2.75 | 639 |
EBITDA per Share of other stocks in the Biotechnology industry
| Issuer | EBITDA per Share | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-15.2 | - | 2.43 % | $ 254 M |  Germany |
 |
Adagene
ADAG
|
-0.63 | $ 2.62 | 28.82 % | $ 147 M |  China |
 |
GlaxoSmithKline plc
GSK
|
1.24 | $ 48.98 | 0.68 % | $ 173 B |  Britain |
 |
Acorda Therapeutics
ACOR
|
-188 | - | -24.86 % | $ 820 K |  USA |
 |
Aeterna Zentaris
AEZS
|
-0.08 | - | 5.93 % | $ 314 M |  Canada |
 |
Alterity Therapeutics Limited
ATHE
|
-1.68 | $ 3.51 | 7.34 % | $ 8.45 B |  Australia |
 |
AgeX Therapeutics
AGE
|
-9.04 K | - | -10.17 % | $ 12.2 K | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
6.75 | - | - | $ 40.3 B | USA |
 |
Grifols, S.A.
GRFS
|
0.87 | $ 9.25 | 1.49 % | $ 6.83 B |  Spain |
 |
Biophytis SA
BPTS
|
-0.23 | - | -13.47 % | $ 169 M |  France |
 |
Aeglea BioTherapeutics
AGLE
|
-6.7 | - | - | $ 1.01 B | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
4.82 | $ 25.92 | -0.86 % | $ 1.26 B | USA |
 |
Midatech Pharma plc
MTP
|
-0.09 | - | -18.52 % | $ 27.3 M | Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
2.22 | - | -1.52 % | $ 24.7 M | USA |
 |
Akero Therapeutics
AKRO
|
-4.25 | - | - | $ 3.67 B | USA |
 |
Ultragenyx Pharmaceutical
RARE
|
-5.53 | $ 24.45 | 4.49 % | $ 2.21 B | USA |
 |
Aptose Biosciences
APTO
|
0.05 | - | -45.71 % | $ 1.2 M | Canada |
 |
Aravive
ARAV
|
-1.92 | - | -13.39 % | $ 1.45 M | USA |
 |
Athira Pharma
ATHA
|
-2.6 | - | - | $ 269 M | USA |
 |
Akouos
AKUS
|
-2.45 | - | 0.23 % | $ 488 M | USA |
 |
AVROBIO
AVRO
|
0.24 | - | 1083.1 % | $ 745 M | USA |
 |
BioLineRx Ltd.
BLRX
|
-0.04 | $ 3.1 | 4.49 % | $ 908 M |  Israel |
 |
Applied Molecular Transport
AMTI
|
-3.2 | - | - | $ 10.1 M | USA |
 |
BioNTech SE
BNTX
|
62.6 | $ 116.27 | -1.86 % | $ 27.2 B | Germany |
 |
Институт стволовых клеток человека
ISKJ
|
-2.69 | - | - | - |  Russia |
 |
Ascendis Pharma A/S
ASND
|
-8.25 | $ 235.41 | 2.95 % | $ 5 B |  Danmark |
 |
BioXcel Therapeutics
BTAI
|
-26.4 | $ 1.84 | 1.66 % | $ 4.66 M | USA |
 |
Burford Capital Limited
BUR
|
1.11 | $ 9.74 | -1.37 % | $ 1.55 B | Britain |
 |
ARCA biopharma
ABIO
|
-5.25 | - | 1052.0 % | $ 415 M | USA |
 |
Aytu BioScience
AYTU
|
-0.39 | $ 2.66 | -1.85 % | $ 16.7 M | USA |
 |
Acasti Pharma
ACST
|
-1.38 | - | 4.01 % | $ 150 M | Canada |
 |
Arrowhead Pharmaceuticals
ARWR
|
0.9 | $ 67.49 | -3.02 % | $ 9.03 B | USA |
 |
Brickell Biotech
BBI
|
-1.17 | - | -5.38 % | $ 6.06 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-0.01 | $ 4.51 | 8.41 % | $ 9.81 B | Israel |
 |
BeiGene, Ltd.
BGNE
|
-0.29 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Ayala Pharmaceuticals
AYLA
|
-2.42 | - | - | $ 7.46 M | Israel |
 |
Adaptimmune Therapeutics plc
ADAP
|
-0.11 | - | -15.15 % | $ 60.3 M | Britain |
 |
AIkido Pharma
AIKI
|
-1.85 | - | 1.93 % | $ 17.4 M | USA |
 |
Albireo Pharma
ALBO
|
-6.41 | - | -0.23 % | $ 916 M | USA |
 |
CureVac N.V.
CVAC
|
-2.22 | - | - | $ 867 M | Germany |
 |
Acer Therapeutics
ACER
|
-1.56 | - | 2.71 % | $ 14 M | USA |
 |
Bellicum Pharmaceuticals
BLCM
|
-0.87 | - | -9.72 % | $ 5.89 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-1.72 | - | - | $ 2.17 B | USA |
 |
AlloVir
ALVR
|
-44.1 | - | 4.14 % | $ 49.1 M | USA |
 |
Coherus BioSciences
CHRS
|
-2.12 | $ 2.04 | 28.3 % | $ 192 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
0.15 | - | -11.43 % | $ 502 K | USA |
 |
Biogen
BIIB
|
4.62 | $ 171.89 | -1.1 % | $ 25 B | USA |
 |
Bio-Path Holdings
BPTH
|
-33 | - | - | $ 100 K | USA |
 |
BioVie
BIVI
|
-12.1 | $ 1.2 | -3.7 % | $ 1.77 M | USA |